Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

January 5, 2023

Study Completion Date

January 5, 2023

Conditions

Myelodysplastic Syndromes

Interventions

DRUG

decitabine

DRUG

tretinoin

GENETIC

DNA methylation analysis

GENETIC

cytogenetic analysis

GENETIC

microarray analysis

OTHER

flow cytometry

OTHER

immunohistochemistry staining method

Trial Locations (1)

Memorial Sloan Kettering Cancer Center, New York

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00382200 - Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes | Biotech Hunter | Biotech Hunter